India Pharma Outlook Team | Tuesday, 14 October 2025
Bristol Myers Squibb (BMS) has made it clear that he is bringing Kopozgo (Mavacamten) to the Indian market. This is the first and only oral, selective cardiac myosin inhibitor for New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (oHCM) adult patients with symptoms in India.
oHCM is a long-term, hereditary heart disorder causing severe symptoms and complications. The symptoms are shortness of breath, light-headedness, and weakness, whereas the complications may be heart failure, abnormal heartbeat, stroke, and death in rare cases. About one out of every 500 people worldwide suffers from the disease, and in India, there are about 2.8 million patients, of which 80–90% patients remain undiagnosed.
The current therapies like beta blockers, calcium channel blockers, and disopyramide mainly only relieve symptoms as well as they do not halt the progression of the underlying disease. Surgical interventions like septal reduction therapy are profoundly invasive and require experience and skills with special equipment leaving a big gap in medical management for these patients.
Also Read: Hikal Opens New HPAPI Lab at Pune Innovation Centre
Kopozgo is one first-in-class, disease-specific therapy for the medical management of obstructive HCM as it targets the main pathophysiological and allows functional capacity and symptom control to be improved. The Indian regulator Central Drugs Standard Control Organisation (CDSCO) has given the go-ahead for the drug following the phase III EXPLORER-HCM and VALOR-HCM trials beta results.
Sanjay Sharma, GM & MD of BMS India, said, “The introduction of Kopozgo brings a novel first-in-class therapy option for the treatment of patients with oHCM, giving great hope to clinicians and patients’ families. The patients enjoy a breakthrough therapy fulfilling the unmet medical need while at the same time they can give them more confidence through their clinical practice.”
